Zheng Meng

Zheng Meng currently serves as the Senior Director of Analytical Development and CMC at Ultragenyx since April 2018, leading efforts in biologics, AAV, and mRNA therapy development. Previously, Zheng worked as a Scientist in Analytical Development at Amgen, where responsibilities included leading the bioassay group for immunology oncology drug development. Prior roles include positions at Biogen focusing on quality control processes, Novavax in analytical development for vaccine potency assays, Maven Biotechnologies in assay development for a real-time imaging platform, and a postdoctoral position at the California Institute of Technology studying DNA damage responses. Zheng holds a B.S. in Biology from Tsinghua University and a Ph.D. in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham.